Literature DB >> 14569053

Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs.

Patrice Colin1, Bijan Ghaleh, Xavier Monnet, Luc Hittinger, Alain Berdeaux.   

Abstract

Lowering heart rate reduces myocardial oxygen consumption (MVO2) and produces potent anti-ischemic effects. The development of selective heart rate-reducing agents represents an alternative approach to the use of beta-blockers. Therefore, our goal was to establish the dose-response curve of the effects of ivabradine (If channel inhibitor) on MVO2 and diastolic time. Seven conscious and chronically instrumented dogs were investigated during exercise at spontaneous and paced heart rate (250 beats/min) after administration of increasing doses of ivabradine (0.25, 0.5, and 1 mg/kg i.v.). During exercise, ivabradine dose dependently and significantly reduced the exercise-induced tachycardia (-17, -21, and -32% at 0.25, 0.5, and 1 mg/kg, respectively, versus saline) without altering myocardial contractility nor mean ejection wall stress. A linear relationship between heart rate (HR) and MVO2 was demonstrated (MVO2 = 0.044 x HR - 1.4; r = 0.987). These effects of ivabradine on MVO2 were abolished by atrial pacing. Similarly, ivabradine dose dependently increased diastolic time without altering the inverse and non linear relationship between diastolic time and heart rate observed with saline. In conclusion, selective heart rate reduction with ivabradine dose dependently increases diastolic time and reduces MVO2 with a linear relationship between heart rate and MVO2. The lack of "on-off" pharmacological profile will predict the possibility of using a wide range of dose regimen.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14569053     DOI: 10.1124/jpet.103.059717

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  42 in total

Review 1.  Heart rate: a forgotten link in coronary artery disease?

Authors:  Kim M Fox; Roberto Ferrari
Journal:  Nat Rev Cardiol       Date:  2011-04-26       Impact factor: 32.419

Review 2.  Is heart rate a treatment target in heart failure?

Authors:  Jan-Christian Reil; Michael Böhm
Journal:  Curr Cardiol Rep       Date:  2012-06       Impact factor: 2.931

3.  Heart rate as an independent risk factor in patients with multiple organ dysfunction: a prospective, observational study.

Authors:  Robert S Hoke; Ursula Müller-Werdan; Christine Lautenschläger; Karl Werdan; Henning Ebelt
Journal:  Clin Res Cardiol       Date:  2011-11-03       Impact factor: 5.460

4.  Cardiomyocyte overexpression of the α1A-adrenergic receptor in the rat phenocopies second but not first window preconditioning.

Authors:  Xin Zhao; Jiyeon Park; David Ho; Shumin Gao; Lin Yan; Hui Ge; Siiri Iismaa; Lin Lin; Bin Tian; Dorothy E Vatner; Robert M Graham; Stephen F Vatner
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-02-03       Impact factor: 4.733

5.  Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise.

Authors:  Robinson Joannides; Nicholas Moore; Michaela Iacob; Patricia Compagnon; Guy Lerebours; Jean-François Menard; Christian Thuillez
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

6.  Age and sex-related differences in dose-dependent hemodynamic response to landiolol hydrochloride during general anesthesia.

Authors:  Ju Mizuno; Ikuto Yoshiya; Takeshi Yokoyama; Yoshitsugu Yamada; Hideko Arita; Kazuo Hanaoka
Journal:  Eur J Clin Pharmacol       Date:  2007-01-09       Impact factor: 2.953

7.  Acute ivabradine treatment reduces heart rate without increasing atrial fibrillation inducibility irrespective of underlying vagal activity in dogs.

Authors:  Kazunori Uemura; Masashi Inagaki; Can Zheng; Toru Kawada; Meihua Li; Masafumi Fukumitsu; Masaru Sugimachi
Journal:  Heart Vessels       Date:  2016-11-14       Impact factor: 2.037

Review 8.  Pharmacological heart rate lowering in patients with a preserved ejection fraction-review of a failing concept.

Authors:  Markus Meyer; Mehdi Rambod; Martin LeWinter
Journal:  Heart Fail Rev       Date:  2018-07       Impact factor: 4.214

Review 9.  Preclinical results with I(f) current inhibition by ivabradine.

Authors:  Alain Berdeaux
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 10.  Ivabradine: potential clinical applications in critically ill patients.

Authors:  Vincenzo De Santis; Domenico Vitale; Anna Santoro; Aurora Magliocca; Andrea Giuseppe Porto; Cecilia Nencini; Luigi Tritapepe
Journal:  Clin Res Cardiol       Date:  2012-10-14       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.